Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity
- PMID: 6185615
- PMCID: PMC2186944
- DOI: 10.1084/jem.157.2.642
Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity
Abstract
The ultraviolet radiation-induced fibrosarcoma 1591 is generally rejected by normal syngeneic mice, but occasionally the tumor succeeds in growing progressively. Analysis of these progressively growing tumors has regularly demonstrated the development of tumor variants that have acquired a heritable progressive growth potential. We have analyzed the phenotypic changes of these variants to determine which kind of selection pressure had occurred during the evolution of the variants, thus giving insight into the relative importance and hierarchy of the different immune defense mechanisms that may be operating in normal individuals as a defense against neoplastic cells. We discovered that all of the host-selected progressor variants had lost not only a strong T cell-recognized and tumor-specific antigen, but also their high sensitivity to cytotoxic macrophages. No selection for macrophage-resistance or loss of the tumor antigen was observed in 1591 tumors reisolated from idiotypically-suppressed mice or from other mice lacking tumor-specific T cell immunity. Analysis of other tumor variants selected in vitro showed that 1591 tumor cells have the potential to lose sensitivity to tumoricidal macrophages without losing the T cell-recognized tumor antigen. Thus the data suggest that T cells and macrophages act together to suppress the outgrowth of potentially malignant cells in vivo.
Similar articles
-
Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells.J Exp Med. 1982 Feb 1;155(2):557-73. doi: 10.1084/jem.155.2.557. J Exp Med. 1982. PMID: 6977009 Free PMC article.
-
Independent immunodominant and immunorecessive tumor-specific antigens on a malignant tumor: antigenic dissection with cytolytic T cell clones.J Immunol. 1983 May;130(5):2461-6. J Immunol. 1983. PMID: 6187859
-
Immune response to progressor variants derived from transfection of an ultraviolet radiation-induced C3H mouse regressor tumor cell line with activated Harvey-ras oncogene.Cancer Res. 1990 Jun 1;50(11):3159-66. Cancer Res. 1990. PMID: 2185882
-
Differential antigen presentation in tumor immunity.Fed Proc. 1984 Jun;43(9):2460-4. Fed Proc. 1984. PMID: 6327399 Review.
-
Correlation between genetic regulation of immune responsiveness and host defence against infections and tumours.Eur J Clin Invest. 1982 Oct;12(5):373-6. doi: 10.1111/j.1365-2362.1982.tb00681.x. Eur J Clin Invest. 1982. PMID: 6816606 Review. No abstract available.
Cited by
-
Tumor growth and evasion of immune destruction: UV-induced tumors as a model.Surv Immunol Res. 1985;4(4):264-70. doi: 10.1007/BF02918734. Surv Immunol Res. 1985. PMID: 2941841
-
Characterization of gene expression profiles of T cells during anti-tumor response.Int J Colorectal Dis. 2005 Nov;20(6):485-93. doi: 10.1007/s00384-004-0714-1. Epub 2005 Apr 6. Int J Colorectal Dis. 2005. PMID: 15812645
-
Characterization of gP85gag as an antigen recognized by Moloney leukemia virus-specific cytolytic T cell clones that function in vivo.J Exp Med. 1985 Jul 1;162(1):128-44. doi: 10.1084/jem.162.1.128. J Exp Med. 1985. PMID: 3891902 Free PMC article. Review.
-
Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines.Proc Natl Acad Sci U S A. 1984 Apr;81(7):2186-90. doi: 10.1073/pnas.81.7.2186. Proc Natl Acad Sci U S A. 1984. PMID: 6609361 Free PMC article.
-
Resistance of tumor cells to tumor necrosis factor.J Clin Immunol. 1988 Sep;8(5):333-41. doi: 10.1007/BF00917148. J Clin Immunol. 1988. PMID: 3053752 Review.